Caribou Biosciences (CRBU) Total Liabilities (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Total Liabilities data on file, last reported at $47.0 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $47.0 million, down 16.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $47.0 million (down 16.75% YoY), and the FY2025 annual result was $53.2 million, down 11.88% from the prior year.
• Total Liabilities eased to $47.0 million in Q1 2026 per CRBU's latest filing, from $53.2 million in the prior quarter.
• Over five years, Total Liabilities peaked at $80.2 million in Q2 2023 and troughed at $47.0 million in Q1 2026.
• A 5-year average of $63.6 million and a median of $63.1 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Liabilities jumped 107.91% in 2022, then declined 22.09% in 2024.
• A 5-year view of Total Liabilities shows it stood at $72.9 million in 2022, then fell by 12.46% to $63.8 million in 2023, then slipped by 5.4% to $60.4 million in 2024, then fell by 11.88% to $53.2 million in 2025, then dropped by 11.68% to $47.0 million in 2026.
• Business Quant data shows CRBU's Total Liabilities at $47.0 million in Q1 2026, $53.2 million in Q4 2025, and $53.1 million in Q3 2025.